Nonablative fractional photothermolysis for facial actinic keratoses: 6-month follow-up with histologic evaluation

1927-nm Fractional resurfacing of facial actinic keratoses: A promising new therapeutic option

“…[2][3][4] However, encouraging data are emerging with nonablative technologies, such as the 1550-nm fractionated erbium-doped fiber laser (Fraxel re :store, Solta Medical) used for treatment of facial AK by Katz et al 5 In their study, 14 men with multiple AK received 5 treatments with 6-month follow-up. Although AK reduction rates remained high at 1 month, the clearance rates declined at 3 and 6 months posttreatment.…”

Management of actinic keratosis: a practical report and treatment algorithm from AKTeamTM expert clinicians

“…Finally, although non-ablative fractional lasers do not significantly reduce the number of AK, they could improve skin quality. 37 Expert opinion: Multiple AK on large surfaces are the target of ultrapulse Er:Yag and CO 2 lasers. However, no randomized study has objectively compared these treatments to other lasers and to other treatment options.…”

Rapid fibrin plug formation within cutaneous ablative fractional CO2 laser lesions

“…Both non-ablative fractional photothermolysis (nFP) and ablative fractional photothermolysis (aFP) have become a major treatment modality for a wide variety of dermatological indications including but not limited to treatments of photoaging, pigmentary disorders, and various types of scars including severe burn scars [5][6][7][8][9][10][11][12][13]. The use of FP for non-melanoma skin cancer is a relatively new field of emerging indication [14][15][16][17][18][19]. It should be noted that FP is used without [14] and in combination with drug delivery [15][16][17][18][19] for treatments of precancerous skin lesions and non-melanoma skin cancer.…”

“…The use of FP for non-melanoma skin cancer is a relatively new field of emerging indication [14][15][16][17][18][19]. It should be noted that FP is used without [14] and in combination with drug delivery [15][16][17][18][19] for treatments of precancerous skin lesions and non-melanoma skin cancer.…”